Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
Is REGN a good investment?
Regeneron Pharmaceuticals, Inc. (REGN) has a Plutrex AI rating of 72.0/100 as of May 27, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Exceptional profitability leadership with 80.9% gross margin vs negative industry average and 29.6% net margin. Main concern: Failed Phase 3 melanoma trial of Fianlimab + Libtayo represents major pipeline setback and revenue impact.
Investment Summary
REGN exhibits exceptional fundamentals with 80.9% gross margin, 29.6% net margin, and fortress balance sheet (0.06 debt-to-equity ratio) but faces significant headwinds from failed Phase 3 melanoma trial and ongoing legal investigations. Trading at PE 15.57 vs industry 38.48 (59.5% discount) with PEG 1.06 indicating fair valuation. Forward EPS growth 16.6% vs historical decline -7.2% suggests turnaround, but news sentiment plummeted to 23.9 due to pipeline setbacks and legal scrutiny.
Key Strengths
- Exceptional profitability leadership with 80.9% gross margin vs negative industry average and 29.6% net margin
- Fortress balance sheet with 0.06 debt-to-equity ratio and $8.75B cash providing strategic flexibility
- Significant valuation discount trading at PE 15.57 vs industry 38.48 (59.5% discount) despite superior fundamentals
Key Concerns
- Failed Phase 3 melanoma trial of Fianlimab + Libtayo represents major pipeline setback and revenue impact
- Multiple ongoing legal investigations creating reputational damage and potential financial liability
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Outstanding financial metrics: ROE 14.6% (vs industry -32.9%), gross margin 80.9% (vs industry -1.3%), operating margin 20.7%, net margin 29.6%, and $8.75B cash with minimal debt (0.06 D/E ratio). Revenue growth 19.0% with projected EPS acceleration to 16.6% next year from recent 3.0% growth. PEG ratio 1.06 indicates fair valuation. Analyst target $838.23 vs current $638.88 suggests 31.2% upside potential. Additional metrics: PE Ratio: 15.57
News Sentiment
Regeneron Pharmaceuticals finds itself under intense scrutiny as multiple law firms launch investigations into potential securities violations following a devastating pipeline setback. The biotech giant's shares have tumbled after its Phase 3 melanoma trial of Fianlimab combined with Libtayo failed to outperform Merck's blockbuster Keytruda, dealing a significant blow to the company's oncology ambitions. Legal firms including SueWallSt, Levi & Korsinsky, and Pomerantz are now investigating claims on behalf of investors, suggesting potential shareholder lawsuits may be brewing. The company reportedly suffered substantial market capitalization losses on May 16, 2026, as investors digested the clinical trial disappointment. However, not all news has been negative, with some regulatory progress noted as the company initiated FDA filings for lonvo-z, indicating continued advancement in other pipeline programs. The legal investigations center around whether Regeneron adequately disclosed risks to investors prior to the trial failure, potentially exposing the company to financial liability and further reputational damage in an already challenging period for the biotech sector.
Risk Assessment
Primary risks include pipeline execution following melanoma trial failure, legal investigation outcomes potentially resulting in financial penalties, and growth deceleration if projected 16.6% EPS acceleration fails to materialize. Mitigation comes from fortress balance sheet providing downside protection and significant valuation discount creating margin of safety.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is REGN a halal stock?
No, Regeneron Pharmaceuticals, Inc. (REGN) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for REGN?
Regeneron Pharmaceuticals, Inc. (REGN) has a Plutrex AI rating of 72.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is REGN a good investment?
According to Plutrex AI, REGN has a Buy rating (72.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in REGN?
US stocks like REGN can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in REGN?
Plutrex AI identifies the main risks for REGN by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.